These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

869 related items for PubMed ID: 33476631

  • 1. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
    Xing L, Fang J, Zhu B, Wang L, Chen J, Wang Y, Huang J, Wang H, Yao X.
    Life Sci; 2021 Mar 15; 269():119068. PubMed ID: 33476631
    [Abstract] [Full Text] [Related]

  • 2. Klotho ameliorates diabetic nephropathy by activating Nrf2 signaling pathway in podocytes.
    Xing L, Guo H, Meng S, Zhu B, Fang J, Huang J, Chen J, Wang Y, Wang L, Yao X, Wang H.
    Biochem Biophys Res Commun; 2021 Jan 01; 534():450-456. PubMed ID: 33256980
    [Abstract] [Full Text] [Related]

  • 3. Atrasentan alleviates high glucose-induced podocyte injury by the microRNA-21/forkhead box O1 axis.
    Wang J, Shen L, Hong H, Li J, Wang H, Li X.
    Eur J Pharmacol; 2019 Jun 05; 852():142-150. PubMed ID: 30876973
    [Abstract] [Full Text] [Related]

  • 4. Klotho plays a protective role against glomerular hypertrophy in a cell cycle-dependent manner in diabetic nephropathy.
    Oh HJ, Nam BY, Wu M, Kim S, Park J, Kang S, Park JT, Yoo TH, Kang SW, Han SH.
    Am J Physiol Renal Physiol; 2018 Oct 01; 315(4):F791-F805. PubMed ID: 29638159
    [Abstract] [Full Text] [Related]

  • 5. Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis.
    He J, Cui J, Shi Y, Wang T, Xin J, Li Y, Shan X, Zhu Z, Gao Y.
    J Diabetes Res; 2023 Oct 01; 2023():7423661. PubMed ID: 37261217
    [Abstract] [Full Text] [Related]

  • 6. Perilipin2 inhibits diabetic nephropathy-induced podocyte apoptosis by activating the PPARγ signaling pathway.
    Dai ZW, Cai KD, Xu LC, Wang LL.
    Mol Cell Probes; 2020 Oct 01; 53():101584. PubMed ID: 32387304
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of overexpressing FoxO1 on apoptosis in glomeruli of diabetic mice and in podocytes cultured in high glucose medium.
    Li W, Wang Q, Du M, Ma X, Wu L, Guo F, Zhao S, Huang F, Wang H, Qin G.
    Biochem Biophys Res Commun; 2016 Sep 16; 478(2):612-7. PubMed ID: 27475499
    [Abstract] [Full Text] [Related]

  • 10. Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome‑mediated inflammation.
    Feng H, Zhu X, Tang Y, Fu S, Kong B, Liu X.
    Int J Mol Med; 2021 Aug 16; 48(2):. PubMed ID: 34278447
    [Abstract] [Full Text] [Related]

  • 11. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway.
    Lei X, Zhang BD, Ren JG, Luo FL.
    Life Sci; 2018 Aug 01; 206():77-83. PubMed ID: 29792879
    [Abstract] [Full Text] [Related]

  • 12. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.
    Guo H, Wang Y, Zhang X, Zang Y, Zhang Y, Wang L, Wang H, Wang Y, Cao A, Peng W.
    Sci Rep; 2017 Jul 31; 7(1):6852. PubMed ID: 28761152
    [Abstract] [Full Text] [Related]

  • 13. Protective effect of silencing Stat1 on high glucose-induced podocytes injury via Forkhead transcription factor O1-regulated the oxidative stress response.
    Wang H, Zhang Y, Xia F, Zhang W, Chen P, Yang G.
    BMC Mol Cell Biol; 2019 Jul 23; 20(1):27. PubMed ID: 31337338
    [Abstract] [Full Text] [Related]

  • 14. Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats.
    Lei X, Zhang L, Li Z, Ren J.
    Drug Des Devel Ther; 2018 Jul 23; 12():2785-2793. PubMed ID: 30233141
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Astragaloside IV prevents high glucose-induced podocyte apoptosis via downregulation of TRPC6.
    Yao XM, Liu YJ, Wang YM, Wang H, Zhu BB, Liang YP, Yao WG, Yu H, Wang NS, Zhang XM, Peng W.
    Mol Med Rep; 2016 Jun 23; 13(6):5149-56. PubMed ID: 27109610
    [Abstract] [Full Text] [Related]

  • 17. Protective effects of klotho on palmitate-induced podocyte injury in diabetic nephropathy.
    Suk Kang J, Son SS, Lee JH, Lee SW, Jeong AR, Lee ES, Cha SK, Chung CH, Lee EY.
    PLoS One; 2021 Jun 23; 16(4):e0250666. PubMed ID: 33891667
    [Abstract] [Full Text] [Related]

  • 18. Dopamine 1 receptor activation protects mouse diabetic podocytes injury via regulating the PKA/NOX-5/p38 MAPK axis.
    Shao X, Zhang X, Hu J, Gao T, Chen J, Xu C, Wei C.
    Exp Cell Res; 2020 Mar 15; 388(2):111849. PubMed ID: 31954110
    [Abstract] [Full Text] [Related]

  • 19. RhoA protects the podocytes against high glucose-induced apoptosis through YAP and plays critical role in diabetic nephropathy.
    Huang Z, Peng Y, Yu H, Yu X, Zhou J, Xiao J.
    Biochem Biophys Res Commun; 2018 Oct 12; 504(4):949-956. PubMed ID: 30220545
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo.
    Du M, Wang Q, Li W, Ma X, Wu L, Guo F, Zhao S, Huang F, Wang H, Qin G.
    Biochem Biophys Res Commun; 2016 Mar 18; 471(4):416-22. PubMed ID: 26902117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.